Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Dermatologic 2Sarcoma 1Other solid neoplasm 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1Breast 1

Conditions

Carcinoma, Renal Cell 17Melanoma 16Kidney Neoplasms 11Neoplasm Metastasis 10Uterine Cervical Neoplasms 9Prostatic Neoplasms 9Breast Neoplasms 7Ovarian Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Anus Neoplasms 6Vaginal Neoplasms 5Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Penile Neoplasms 5Pancreatic Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Hepatocellular 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Oropharyngeal Neoplasms 4Lymphoma 4Lung Neoplasms 4Colorectal Neoplasms 4Carcinoma, Merkel Cell 4Vulvar Neoplasms 3Neuroblastoma 3Multiple Myeloma 3Head and Neck Neoplasms 3Esophageal Neoplasms 3Wilms Tumor 2

Interventions

pembrolizumab 3Nivolumab 3atezolizumab 2fludarabine 1epacadostat 1durvalumab 1avelumab 1aldesleukin 1Interleukin-2 1Docetaxel 1Cyclophosphamide 1Carboxylesterase 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Microsatellite Instability × fludarabine × Genitourinary × Clear all
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡